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Abstract
Background/Objective
Genetic polymorphisms in the inosine triphosphatase (ITPA) gene have been associated
with the protection from early ribavirin(RBV)-induced hemolytic anemia among patients with
chronic hepatitis C virus (HCV) infection. The aim of the present study was to investigate
the association between the functional ITPA variants and hematological side effects during
antiviral therapy with pegylated interferon (PegIFN) and RBV.
Patients and Methods
This cohort study included all consecutive Caucasian patients treated for chronic HCV
infection with PegIFN and RBV between 2000 and 2009 for whom a serum sample was
available for genetic testing. The predicted inosine triphosphate pyrophosphatase (ITPase)
activity was based on the genotypes of the SNPs rs1127354 and rs7270101. Decline in
hemoglobin (Hb) during antiviral therapy, as well as dose reductions, blood transfusions
and use of erythropoietin were assessed.
Results
In total, 213 patients were included. The predicted ITPase activity was normal among 152
(71%) patients; 61 (29%) patients had ITPase deficiency. By multivariable linear regression,
RBV dose in mg per kilogram (Beta 0.09, 95%CI 0.04–0.13, p<0.001) and normal ITPase
activity (Beta 0.89, 95%CI 0.64–1.14, p<0.001) were associated with more Hb decline at
week 4 of treatment. Patients with normal ITPase activity underwent more dose adjust-
ments of RBV than patients with ITPase deficiency (19(13%) vs 1(2%),p = 0.014) and
received erythropoietin more frequently (12 (8%) vs 0 (0%),p = 0.024).
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Conclusion
Genetic variants in the ITPA gene protected against RBV treatment-induced anemia among
Caucasian patients with chronic HCV infection. Patients with normal ITPase activity under-
went more dose reductions of RBV and received erythropoietin more frequently.
Introduction
Currently, there is a changing paradigm in the treatment of chronic hepatitis C virus (HCV)
infection. Although it is expected that the efficacy and safety of antiviral therapy improves con-
siderably with the introduction of direct acting antivirals (DAAs), the high costs may limit the
availability of these new drugs. Therefore, pegylated interferon (PegIFN) and ribavirin (RBV)
containing regimens are likely to remain important treatment options in many countries around
the world, also in high-income countries. Furthermore, some studies showed that the addition of
RBV to DAAs could be beneficial in selected cases [1, 2]. Unfortunately, PegIFN and RBV are
associated with many side effects, including cytopenias. These cytopenias occur frequently and
are the most important reasons for dose reductions [3, 4]. As these dose reductions compromise
treatment efficacy [5, 6], it is of great importance to select patients who are at greatest risk for
these hematological side effects. These patients may benefit from strategies to optimise treatment
adherence, such as early administration of supportive hematopoietic growth factors.
Recently, two genetic polymorphisms in the inosine triphosphatase (ITPA) gene on chro-
mosome 20 were shown to be associated with protection against early RBV-induced hemolytic
anemia during therapy with PegIFN and RBV [7]. The first polymorphism concerns a missense
variant in exon 2 (rs1127354), the second concerns a splicing-altering single nucleotide poly-
morphism (SNP) in intron 2 (rs7270101). These two functional variants cause ITPase defi-
ciency, subsequently preventing the depletion of erythrocyte adenosine triphosphate (ATP)
and oxidative damage on the erythrocyte membrane [8]. Although ITPase deficiency is protec-
tive against anemia, it has been associated with a greater decline in platelet count during
PegIFN and RBV therapy [9, 10]. It has been suggested that patients with normal ITPase activ-
ity have a higher chance to develop thrombocytosis in reaction to the decline in hemoglobin
(Hb). Although the exact mechanisms for this reactive thrombocytosis have not been
completely elucidated, the increased stimulation of megakaryocyte-erythoroid progenitor cells
by erythropoietin (EPO) production is thought to be of major importance [11, 12].
The association of the ITPA variants with the occurrence of RBV-induced hemolytic anemia
has been previously assessed [9, 10, 13, 14]. However, these studies were based on patients included
in randomised controlled trials with strict inclusion criteria and dosing rules. It can be questioned
whether these findings also apply for the general patient population treated with PegIFN and RBV
in field practice, where dose reductions are less strictly applied. Therefore, the aim of this study was
to investigate the relationships between functional ITPA variants and hematological side effects of
PegIFN and RBV therapy in routine daily practice. Secondly, the relations between these genetic
polymorphisms and the occurrence of PegIFN and RBV dose reductions, administration of EPO
and blood transfusions and virological response to antiviral therapy was analysed.
Patients and Methods
Patients
All Caucasian patients of whom a blood sample was available for genetic testing were included
from our previously described cohort, which includes all consecutive patients with chronic
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HCV infection who were treated with PegIFN alfa-2a or -2b and RBV between 2000 and 2009
in our center [15, 16]. The inclusion and exclusion criteria for this study are described else-
where [15, 16]. Briefly, patients were included if they were treated with PegIFN and RBV
between 2000 and 2009. Patients treated with conventional interferon and patients co-infected
with human immunodeficiency virus or the hepatitis B virus were excluded. In order to prevent
confounding by ethnic origin, only Caucasian patients were included in the present study.
The study was conducted in accordance with the guidelines of the Declaration of Helsinki
and the principles of Good Clinical Practice. The ethical review board of the Erasmus Medical
Center, Rotterdam, The Netherlands approved this study as it was considered to be a low-risk
study using retrospective and anonymized patient data. Written informed consent was
obtained from each patient for storage of serum samples.
Data acquisition
We obtained baseline data on gender, age, race, body mass index, METAVIR score, HCV geno-
type, previous interferon-based treatment, platelet count, absolute neutrophil counts, Hb, biliru-
bin and albumin concentration, glucose levels, presence of hemophilia and use of anticoagulants
and antiplatelet therapy, diabetes mellitus (DM), history of heroin use and/or smoking.
During therapy all patients visited the outpatient clinic in one to six weeks intervals. At
every visit blood tests were performed and patients were assessed for dose reductions and dis-
continuation of antiviral therapy. Among patients who were treated within a standard of care
protocol, PegIFN and RBV dose reductions were made at the discretion of the treating physi-
cian. Patient characteristics such as age, physical condition, virological response, comorbidities
and side effects of antiviral therapy were taken into account when considering a dose reduction.
All study protocols of the clinical trials stated that dose reductions should be made according
to product labels. However, these guidelines were not applied in some patients, due to the
expected decrease of antiviral efficacy. Therefore these patients were treated at the discretion of
the treating physician as well. The use of blood transfusion and EPO were also registered.
Endpoints
The primary endpoint was the decline in Hb (mmol/L) and platelet count (109/L) which was
assessed at week 4 (+/-7 days). This time point was chosen in order to limit the influence of
dose reductions on these hematological outcomes [7]. A clinically significant decline in Hb was
defined as a decrease of at least 3.0 g/dL (1.86 mmol/L) or an absolute value lower than 10 g/dL
(6.21 mmol/L). These thresholds were also used in other studies on ITPase deficiency [13, 14,
17]. Anemia was defined according to the thresholds used by the World Health Organization;
for women a Hb concentration below 7.45 mmol/L and for men below 8.1 mmol/L were used
as cut-off. Thrombocytopenia was defined as a platelet count below 150109/L. A clinical rele-
vant thrombocytopenia was defined as a platelet count below 50109/L, since current guidelines
advise to reduce the dose of PegIFN when platelet counts fall below 50109/L [18].
As a secondary endpoint, the decline in Hb and platelet counts were also assessed at week 8
and 12 (+/-7 days) of antiviral therapy, as well as the nadir values of these parameters.
Sustained virological response (SVR) was defined as HCV RNA negativity in blood six
months after cessation of antiviral therapy. Dose reductions of RBV and PegIFN, as well as the
administration of EPO and blood transfusion, were considered as clinical endpoints.
Genotyping methods
Serum samples stored at -20° or -80° Celsius were used for DNA extraction and genotyping
procedures, which were carried out centrally at LGC genomics. Purified genomic DNA of
ITPA Polymorphisms and Antiviral Therapy
PLOS ONE | DOI:10.1371/journal.pone.0139317 October 6, 2015 3 / 14
5 ng was used for genotyping. Genotypes were assigned using all of the data from the study
simultaneously. Genotype sequences were derived from NCBI. Genetic analyses were per-
formed at the polymorphic sites rs12979860 (19:39248147, near IL28B, also known as inter-
feron-λ3), rs1127354 (20:3213196, ITPA–1) and rs7270101 (20:3213247, ITPA–2). The IL28B
SNP rs12979860 was chosen, since it best describes the association with sustained SVR for all
genotypes [19–21]. Linkage disequilibrium and Hardy-Weinberg equilibrium (HWE) were
tested for these SNPs using SNAP and OEGE [22].
Predicted ITPase activity
As freshly acquired erythrocytes were lacking in order to directly measure ITPase activity, the
predicted ITPase activity was based on genotypes of both ITPA–1 and ITPA–2 as is determined
by previous analyses [23, 24]. Patients with normal ITPase activity (i.e. 100%) were defined as
patients with the combined presence of CC-genotype and AA-genotype for rs1127354 and
rs7270101 respectively (S1 Table). Patients with less than 100% ITPase activity were defined as
patients with ITPase deficiency (non-CC-genotype and non-AA-genotype for rs1127354 and
rs7270101 respectively, S1 Table).
Statistical Analysis
Continuous variables were summarised as median (interquartile range [IQR]) and categorical
variables as frequencies (percentages). Comparisons between groups were performed using X2
test for categorical variables or the Mann-Whitney U test for comparing medians. The genetic
association analyses for ITPA and IL28B polymorphisms consisted of a dominant genetic
model (CC- and AA-genotype vs non-CC- and non-AA-genotype for ITPA and CC-genotype
vs non-CC genotype for IL28B) [14, 25]. Linear regression analysis determined which variables
were associated with the absolute decline in Hb and platelet count at week 4. Logistic regression
was performed to determine which variables were associated with a clinically significant Hb
decline at week 4, SVR and virological relapse. For decline in Hb and platelet count, a sensitiv-
ity analysis was performed which excluded patients whom were treated with a high PegIFN
dose induction regimen. Age, sex and variables with a p-value of0.2 in univariable analyses
were included in multivariable analyses. All final models were created by using a backward
stepwise method, in order to select the variables that were significantly and independently asso-
ciated. Potential confounding was checked. All statistical tests were two-tailed, and p<0.05 was
considered to be statistically significant. The significance level of interactions was set at 0.01 in
order to correct for multiple testing. SPSS version 21.0 (SPSS, Chicago, IL) was used.
Results
Patients
In total, 321 consecutive patients with chronic HCV infection were treated with PegIFN and
RBV between 2000 and 2009, of which 256 were Caucasian. Two hundred thirteen (83%) of
these patients, who had a sample available for genetic testing and could be genotyped for both
ITPA polymorphisms, were included in the current analyses (S1 Fig). Median age was 45 years
(IQR 39–50), 145 (68%) were male, 105 (49%) had HCV genotype 1, and 39 (18%) had cirrho-
sis. Of the included patients, 140 were treated within a standard of care protocol. The remain-
ing 73 patients were treated within clinical studies: 61 patients participated in three clinical
trials and received a standard of care with PegIFN alfa-2a (180μg/week) or -2b (1.5μg/kg/week)
plus weight based RBV. The remaining 12 patients received a PegIFN induction regimen with
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either PegIFN alfa-2a (270–360 μg/week) for 24 weeks or PegIFN alfa-2b (2.0–3.0 μg/kg/week)
for 24 weeks followed by 48 weeks of PegIFN and daily weight-based ribavirin.
Genotyping
The majority of patients were homozygous carriers of the major allele for ITPA–1 (rs1127354
C) and ITPA–2 (rs7270101 A), respectively 200 (89%) and 170 (76%) patients. The minor allele
frequency (MAF) was 0.04 for ITPA–1 (rs1127354 A) and 0.13 for ITPA–2 (rs7270101 C).
Eighty-two of the patients (36%) had the favourable IL28B genotype (rs12979860 CC); MAF
was 0.39 (rs12979860 T). All SNPs were in HWE and not in linkage disequilibrium (r20.012).
The call rates were 96% (217/226), 98% (221/226) and 96% (217/226), for ITPA–1, ITPA–2 and
IL28B respectively.
S1 Table shows the distribution of the predicted ITPase activity according to the genotype
of ITPA–1 and ITPA–2. In total, 152 (71%) patients had normal ITPase activity and 61 (29%)
patients had ITPase deficiency. Baseline characteristics were compared between patients with
normal ITPase activity and patients with ITPase deficiency (Table 1).
ITPase deficiency and on-treatment hemoglobin concentration
In total, 182 (85%) patients experienced at least one episode of anemia during antiviral treat-
ment and in 157 (74%) patients a clinically significant decline in Hb was reported. At baseline,
median Hb concentration was 9.2 mmol/L (IQR 8.7–9.9) for patients with normal ITPase
activity and 9.3 mmol/L (IQR 8.7–9.9) for patients with ITPase deficiency (p = 0.793). At treat-
ment weeks 4, 8 and 12, median Hb concentration was significantly lower among patients with
normal ITPase activity (p<0.001 for all time points, Fig 1A). The nadir median Hb concentra-
tion was lower for patients with normal ITPase activity compared to patients with ITPase defi-
ciency, respectively 6.6 mmol/L (IQR 5.8–7.2) and 7.2 mmol/L (IQR 6.6–8.1, p<0.001).
Furthermore, patients with ITPase deficiency had a lower occurrence of a clinically significant
decline in Hb as compared to patients without ITPase deficiency at week 4, 8 and 12 (p<0.001
for all timepoints, S2 Fig).
Multivariable linear regression analysis showed that baseline platelet count (Beta -0.02, 95%
CI -0.04–-0.00, p = 0.022), baseline Hb concentration (Beta 0.44, 95% CI 0.29–0.59, p<0.001),
RBV dose per kilogram body weight (Beta 0.09, 95% CI 0.04–0.13, p<0.001) and normal
ITPase activity (Beta 0.89, 95% CI 0.64–1.14, p<0.001) were associated with the absolute
decline in Hb concentration at week 4 of treatment (Table 2). The interaction terms between
the variables in the final model were not statistically significant. Also in a sensitivity analysis
for which patients with a PegIFN induction regimen were excluded the presence of normal
ITPase activity was associated with the occurrence of a significant decline in Hb concentration
at week 4 (Beta 0.91, 95% CI 0.65–1.18, p<0.001).
In multivariable logistic regression analysis, the occurrence of a significant decline, as a
dichotomous variable, was associated with baseline Hb concentration (OR 2.31, 95% CI 1.47–
3.64, p<0.001), RBV dose per kilogram body weight (OR 1.41, 95% CI 1.19–1.67, p<0.001)
and normal ITPase activity (OR 11.5, 95% CI 4.24–31.1, p<0.001) (S2 Table). Again, in a sensi-
tivity analysis among patients without a PegIFN induction regimen, the presence of normal
ITPase activity was associated with the occurrence of a significant decline in Hb concentration
at week 4 (OR 13.4, 95% CI 4.61–39.0, p<0.001).
ITPase deficiency and on-treatment platelet counts
Median platelet count was only significantly higher at week 4 of treatment among patients with
normal ITPase activity compared to patients with ITPase deficiency (144x109/L, (IQR 103–
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196) vs 132x109/L, (IQR 99–160); p = 0.040, Fig 1B). At least one episode of thrombocytopenia
was present among 166 (78%) patients, of which 22 (10%) had a platelet count below 50x109/L.
Only ten (5%) patients experienced a platelet count below 50 x 109/L at week 4 of treatment.
The occurrence of a platelet count below 50 x 109/L among patients with normal ITPase
Table 1. Baseline characteristics.
Baseline variable Total b Normal ITPaseactivity a, b ITPase deﬁciency a,b p-value
N = 213 n = 152 n = 61
Age 45 (39–50) 44 (38–49) 46 (40–54) 0.25
Male 145 (68%) 100 (66%) 45 (74%) 0.26
BMI in kg/m2 a, c 26.0 (23.7–28.1) 25.8 (23.3–28.0) 26.4 (24.1–30.3) 0.13
HCV Genotype a 0.20
1 105 (49%) 76 (50%) 29 (48%)
2 19 (9%) 11 (7%) 8 (13%)
3 76 (36%) 53 (35%) 23 (38%)
4 13 (6%) 12 (8%) 1 (2%)
Histology / elastography METAVIR score d 0.47
F0-1 69 (32%) 54 (38%) 15 (28%)
F2 67 (32%) 46 (33%) 21 (39%)
F3 20 (9%) 16 (11%) 4 (7%)
F4 39 (18%) 25 (18%) 14 (26%)
Hemoglobin, in mmol/L 9.3 (8.7–9.9) 9.2 (8.7–9.9) 9.3 (8.7–9.9) 0.79
Anemia e 8 (4%) 5 (3%) 3 (5%) 0.57
Platelet count, in platelet x 109/L 197 (152–234) 198 (154–234) 191 (145–241) 0.38
Thrombocytopenia e 48 (23%) 31 (20%) 17 (28%) 0.24
Absolute neutrophil count, in cells/μL c 3200 (2500–4200) 3400 (2700–4400) 2800 (2300–3500) 0.022
Albumin, in g/L 44 (42–46) 44 (42–46) 44 (42–45) 0.22
Bilirubin, in μmol/L 10 (7–13) 10 (7–13) 10 (7–14) 0.75
Prothrombin time, in seconds 12.4 (11.7–13.2) 12.4 (11.7–13.2) 12.5 (11.8–13.5) 0.76
AST/ALT ratio a, c 0.73 (0.54–1.0) 0.74 (0.55–0.98) 0.72 (0.52–1.0) 0.91
Gamma-gt, in IU/L c 62 (33–118) 62 (33–111) 63 (39–150) 0.29
Creatinin, in mmol/L c 71 (63–80) 71 (63–80) 70 (67–76) 0.57
HCV RNA load < 800,000 IU/mL a, c 60 (28%) 35 (26%) 25 (46%) 0.007
Use of anticoagulants 7 (3%) 4 (3%) 3 (5%) 0.40
Presence of haemophilia 11 (5%) 8 (5%) 3 (5%) 0.92
Presence of DM a 12 (6%) 11 (7%) 1 (2%) 0.11
Smoking 129 (61%) 92 (66%) 37 (69%) 0.71
History of IV drug use a 121 (57%) 82 (55%) 39 (66%) 0.15
PegIFN alfa-2a a 151 (71%) 112 (74%) 39 (64%) 0.16
PegIFN induction regimen a 12 (6%) 10 (7%) 2 (3%) 0.36
Dose of RBV, in mg/kg 13.2 (11.8–14.5) 13.5 (12.0–14.6) 12.8 (10.3–14.1) 0.036
a. Abbreviations: ITPase, inosine triphosphaye pyrophosphatase; BMI, body mass index; HCV, hepatitis C virus; AST, aspartate aminotransferase; ALT,
alanine aminotransferase; DM, diabetes mellitus; IV, intravenous; PegIFN, pegylated interferon; RBV, ribavirin
b. Medians are presented as number (IQR). Numbers are presented as n, (percentage of whole group)
c. Variables with a ‘c’ were missing in  10%
d. Liver biopsy or elastography was available in 195 patients
e. Anemia was deﬁned as a Hb concentration below 8.1 mmol/L for men and below 7.45 mmol/L for women, thrombocytopenia was deﬁned as a platelet
count below 150*109/L
doi:10.1371/journal.pone.0139317.t001
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activity (4%) and patients with ITPase deficiency (7%) was comparable (p = 0.418). When the
whole treatment period was taken into account, the occurrence of a platelet count below 50 x
109/L was still similar between patients with normal ITPase activity and ITPase deficiency
(11% vs 10%, respectively, p = 0.881).
Fig 1. Median hemoglobin and platelet count.Median hemoglobin (A) and platelet counts (B) at baseline, at week 4, 8 and 12 and the nadir hemoglobin
and platelet count during treatment. Dashed line represents the patients with ITPase deficiency and the black line represents patients with normal ITPase
activity. Abbreviations: ITPase, inosine triphosphaye pyrophosphatase.
doi:10.1371/journal.pone.0139317.g001
Table 2. Univariable andmultivariable linear regression analysis for absolute hemoglobin decline at week 4.
Baseline variable Univariable Multivariable b
Beta (95% CI) a p-value Beta (95% CI) a p-value
Age, per year 0.05 (-0.09–0.02) 0.473 0.04 (-0.01–0.02) 0.535
Female gender -0.09 (-0.38–0.20) 0.545 0.24 (-0.03–0.50) 0.086
Cirrhosis 0.09 (-0.26–0.44) 0.628
DM a -0.01 (-0.60–0.59) 0.984
BMI a -0.01 (-0.05–0.02) 0.490
Platelet count, per 10x109/L -0.02 (-0.04–0.00) 0.115 -0.02 (-0.04–-0.00) 0.022
Hb, per mmol/L a 0.36 (0.21–0.52) <0.001 0.44 (0.29–0.59) <0.001
PegIFN 2b vs PegIFN 2a -0.08 (-0.38–0.22) 0.583
PegIFN induction regimen a 0.37 (-0.20–0.94) 0.203
RBV dose, per mg/kg a 0.11 (0.05–0.16) <0.001 0.09 (0.04–0.13) <0.001
Treatment naïve 0.05 (-0.31–0.42) 0.776
Presence of hemophilia 0.44 (-0.21–1.09) 0.184
Use of anticoagulants -0.26 (-1.00–0.48) 0.490
HCV Genotype (2/3 vs 1/4) a -0.38 (-0.65–-0.11) 0.006
IL28B (CC vs CT/TT) a -0.12 (-0.40–0.17) 0.422
ITPA–1 (CC vs CA/AA) a 1.02 (0.52–1.51) <0.001
ITPA–2 (AA vs AC/CC) a 0.81 (0.50–1.12) <0.001
Normal ITPase activity a 0.93 (0.66–1.21) <0.001 0.89 (0.64–1.14) <0.001
a. Abbreviations: CI, conﬁdence interval; DM, diabetes mellitus; BMI, body mass index; Hb, hemoglobin; PegIFN, pegylated interferon; RBV, ribavirin;
HCV, hepatitis C virus; IL28B, interleukin-28B; ITPA, inosine triphosphatase; ITPase, inosine triphosphaye pyrophosphatase
b. The ﬁnal model was created by using a backward stepwise method. Confounding was checked.
doi:10.1371/journal.pone.0139317.t002
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In multivariable linear regression analysis, adjusted for Hb decline, baseline platelet count (per
10 x 109/L, Beta 2.55, 95%CI 1.73–3.38, p<0.001) and cumulative dose of PegIFN (per 100 mcg,
Beta 4.86, 95%CI 2.75–6.98, p<0.001) were associated with more decline in platelet count at week
4, wheras the presence of normal ITPase activity (Beta -18.5, 95%CI -29.7–-7.31, p = 0.001) was
significantly associated with less decline in platelet count at week 4 (Table 3). When patients with
a PegIFN induction regimen were excluded, presence of normal ITPase activity was still associ-
ated with less decline in platelet count (Beta -16.5, 95%CI -27.6–-5.33, p = 0.004).
ITPase deficiency, dose reductions, EPO and blood transfusions
In total, 20 (9%) patients underwent at least one dose reduction of RBV and 44 (21%) patients
at least one dose reduction of PegIFN. At least one blood transfusion was given to 27 (13%)
patients and 12 (6%) patients received at least one dose of EPO. Nineteen (13%) patients with
normal ITPase activity underwent at least one dose reduction of RBV, whereas one (2%)
patient with ITPase deficiency underwent at least one dose reduction (p = 0.014, Fig 2). The
dose of PegIFN was reduced among 36 (24%) patients with normal ITPase activity and among
eight (13%) patients with ITPase deficiency (p = 0.085). Blood transfusion and EPO were
administered to 23 (15%) and twelve (8%) patients with normal ITPase; and to 4 (7%) and
none (0%) of the patients with ITPase deficiency (p = 0.089 and p = 0.024, respectively).
ITPase deficiency and virologic response
In total, 123 (58%) patients attained SVR, 45 (21%) patients had a virological relapse and 43
(20%) were non-responder. Two patients, who were both HCV RNA negative at the end of
Table 3. Univariable andmultivariable linear regression analysis for absolute decline in platelet count at week 4.
Baseline variable Univariable Multivariable b
Beta (95% CI) a p-value Beta (95% CI) a p-value
Age, per year -0.75 (-1.35–-0.15) 0.015 -0.44 (-9.46–2.32) 0.233
Female gender 7.13 (-5.25–19.5) 0.257 6.15 (-4.69–17.0) 0.265
Cirrhosis -5.10 (-19.8–9.62) 0.495
DM a -3.23 (-28.2–21.8) 0.799
BMI a -0.22 (-1.71–1.28) 0.776
Platelet count, per 10x109/L 2.49 (1.60–3.37) <0.001 2.55 (1.73–3.38) <0.001
Hb, per mmol/L a -1.06 (-8.04–5.92) 0.765
Hb decline, per mmol/L a -7.89 (-13.8–-1.93) 0.010 -3.57 (-9.46–2.32) 0.233
PegIFN 2b vs PegIFN 2a a -15.0 (-27.5–-2.43) 0.020
PegIFN induction regimen a 13.9 (-10.0–37.9) 0.253
Cumulative dose of PegIFN, per 100 mcg a 4.45 (2.12–6.78) <0.001 4.86 (2.75–6.98) <0.001
RBV dose, per mg/kg a -1.21 (-3.61–1.19) 0.320
HCV Genotype (2/3 vs 1/4) a 3.69 (-8.00–15.4) 0.534
IL28B (CC vs CT/TT) a -5.76 (-17.9–6.40) 0.351
ITPA–1 (CC vs CA/AA) a -18.2 (-39.8–3.26) 0.096
ITPA–2 (AA vs AC/CC) a -9.54 (-23.4–4.33) 0.177
Normal ITPase activity a -14.9 (-27.5–-2.19) 0.022 -18.5 (-29.7–-7.31) 0.001
a. Abbreviations: CI, conﬁdence interval; DM, diabetes mellitus; BMI, body mass index; Hb, hemoglobin; PegIFN, pegylated interferon; RBV, ribavirin;
HCV, hepatitis C virus; IL28B, interleukin-28B; ITPA, inosine triphosphatase; ITPase, inosine triphosphaye pyrophosphatase
b. The ﬁnal model was created by using a backward stepwise method. Confounding was checked.
doi:10.1371/journal.pone.0139317.t003
ITPA Polymorphisms and Antiviral Therapy
PLOS ONE | DOI:10.1371/journal.pone.0139317 October 6, 2015 8 / 14
treatment, were lost to follow-up before being able to assess the sustainability of their virologi-
cal response. Neither polymorphisms in the ITPA gene (IPTA–1 CC vs. CA/AA, OR 1.84 95%
CI 0.66–5.15, p = 0.24; ITPA–2 AA vs AC/CC, OR 1.03 95% CI 0.54–1.97, p = 0.92) nor the
presence of normal ITPase activity (OR 1.23, 95% CI 0.68–2.24, p = 0.50) were associated with
SVR. In multivariable logistic regression analyses, age (per year, OR 0.94, 95% CI 0.90–0.98,
p = 0.004), baseline gamma-glutamyltransferase (per U/L, OR 0.99, 95% CI 0.99–1.00,
p = 0.016), HCV genotype (2/3 vs 1/4, OR 4.26, 95% CI 1.89–9.63, p<0.001) and IL28B geno-
type (CC vs CT/TT, OR 5.06, 95% CI 2.16–11.9, p<0.001) were associated with SVR (S3
Table).
Univariable logistic regression analysis showed that the presence of normal ITPase activity
was not significantly associated with virological relapse (OR 0.67, 95% CI 0.34–1.36, p = 0.27).
Multivariable logistic regression analysis showed that only age (OR 1.05, 95% CI 1.01–1.10,
p = 0.02) was significantly associated with virological relapse.
Discussion
This large cohort study in a real world setting found that genetic polymorphisms in the ITPA
gene, resulting in ITPase deficiency, were associated with less Hb decline during pegIFN and
RBV therapy among Caucasian patients with chronic HCV infection. Patients with normal
ITPase activity were at higher risk to undergo dose reductions of both PegIFN and RBV,
receive blood transfusions and be administered EPO. These patients may benefit from early
administration of supportive hematopoietic growth factors in order to improve treatment
adherence. Furthermore it could be a helpful tool in the decision of adding RBV, which has
shown to be of additional value for some IFN-free regimens [1, 2].
Fig 2. ITPase deficiency, dose reductions, EPO and blood transfusions. Percentage of patients with at
least one dose reduction of RBV or PegIFN, at least one blood transfusion or one dose of EPO during
treatment. White bars represent the patients with normal ITPase activity and the black bars represent patients
with ITPase deficiency. Abbreviations: ITPase, inosine triphosphate pyrophosphatase; RBV, ribavirin;
PegIFN, pegylated interferon; EPO, erythropoietin.
doi:10.1371/journal.pone.0139317.g002
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Patients with ITPase deficiency (27% of our cohort) experienced lower declines in Hb con-
centration compared to patients with normal ITPase activity during the first four weeks of anti-
viral treatment. As expected, besides the presence of normal ITPase activity, RBV dose was also
associated with a significant decline in Hb at week 4. The results of the present study confirm
observations described in previous studies [9, 13, 14]. More important, our study revealed that
patients with normal ITPase activity underwent more dose adjustments for RBV (13% vs 2%),
and more often EPO was administered (8% vs 0%). Two previous studies among patients with
HCV genotype 2 and 3 found no association between the ITPase activity and the need for RBV
dose reductions [9, 14]. In the first study, including 238 patients with HCV genotype 2 and 3,
RBV dose was reduced in 35 patients (15%) [14]. The presence of ITPase deficiency was not
statistically associated with a lower hazard ratio (HR) for RBV dose reductions (HR 0.80, 95%
CI 0.35–1.71, p = 0.57). This study used weight-based RBV and the dose was not reduced until
Hb concentration fell below 5.9 mmol/L (i.e. 9.5 g/dL). The second study included 349 patients
with HCV genotype 2 and 3, which showed that 6% of the patients did not receive the full
planned dose of RBV. This low rate can be attributed to the use of low-dose RBV (i.e. 800 mg/
day) and the shorter treatment duration among this patients. In contrast, and in line with our
data, a study among solely HCV genotype 1 infected patients did describe that the presence of
ITPase deficiency resulted in fewer RBV dose reductions [13]. A high rate of RBV dose reduc-
tions was found in this study (47%), attributed to the fact that they included missed doses in
this rate. Only four patients in this trial received EPO. In general, these data were based on clin-
ical trial cohorts, solely including selected patients with specific HCV genotypes, different
doses of RBV as well as limited use of blood transfusion and EPO. Furthermore these studies
used strict dosing rules, instead of dose adjustments according to the treating physician, which
is more representative for the clinical setting. Recently, another real-world study, also including
all HCV genotypes, found that patients with ITPase deficiency required less RBV dose reduc-
tions and less EPO [17]. In 18% of the patients with ITPA deficiency a RBV dose reductions
was required, whereas 41% of the patients with normal ITPase activity underwent at least one
dose reductions of RBV. However, this study used strict dosing rules as well, which is not an
optimal reflection of daily practice. Moreover, they did not report on the ethnic background of
patients, which is essential in genetic studies [25].
The presence of ITPase deficiency was also associated with a deeper decline in platelet count
at week 4 of treatment, which could be explained by the absence of thrombocytosis in reaction
to the hemolytic anemia. This is in line with previous studies which showed that reduced
ITPase activity, which protects against RBV-induced anemia, is associated with the occurrence
of treatment-induced thrombocytopenia [9, 10, 26]. ITPase deficiency was not related to the
occurrence of a platelet count below 50 x 109/L, but this rarely happens among patients with
chronic HCV infection who are treated with pegIFN and RBV. Indeed, also in the current
study, only 10% of patients had a platelet count below 50 x 109/L during their treatment course.
Nevertheless, it could be a predictive tool among patients with cirrhosis, who are more prone
to develop severe thrombocytopenia [27].
We did not find ITPase deficiency to be associated with virological response to PegIFN and
RBV, perhaps because of limited power in our current study. Data on the influence of ITPase
activity on the virological response is inconclusive, probably due to the inclusion of various
HCV genotypes, heterogeneity in treatment regimens and the various ways in which the associ-
ation was analysed. Our results are in line with the largest study to date, among patients with
HCV genotype 1, which did not show a relation between ITPase deficiency and SVR either
[13]. Nevertheless, it could be hypothesised that the higher frequency of dose reductions
among patients with normal ITPase activity would compromise treatment efficacy, as was
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reported previously [5, 6]. However, the mechanism by which anemia and ITPase deficiency
influence virological response is still not fully unravelled.
The clinical importance of ITPA polymorphisms in the era of regimes with DAAs could be
debated. Although limited data is available, previous studies among patients treated with triple
therapy including telaprevir also showed that a ITPA polymorphism (rs1127354) was associ-
ated with the development of on-treatment anemia [28–30]. Unfortunately, these studies are
solely among patients of Asian ancestry, and these patients are monoallellic for ITPA polymor-
phism rs7270101. In contrast to these results, the limited data available for Caucasian patients
showed contrasting results[31]. Among patients with advanced hepatic fibrosis, ITPA poly-
morphisms were associated with the severity of Hb decline at week 4, but not at week 12 of
therapy. This effect was attributed to the increased plasma levels of RBV after the first 4 weeks
of triple therapy[32]. Recently, it was shown that ITPA polymorphisms were also associated
with anemia during IFN-free therapy [33]. Studies on the impact of RBV dose reductions
among patients treated with triple therapy, including PegIFN, RBV and boceprevir, demon-
strated that a lower dose of RBV did not affect SVR rates [34, 35]. Moreover, RBV dose reduc-
tions among patients with HCV genotype 2 and 3, treated with IFN-free regimens, also
suggested no effect on SVR rates [36, 37]. Nevertheless, as RBV will still be a component of
IFN-free treatment regimens, ITPA polymorphisms can select patients who are prone to
develop RBV-induced hemolytic anemia in order to apply more conservative and/ or earlier
dose reductions or early administration of supportive agents. Secondly, it may be used as an
additive tool to select a specific IFN-free regimen for the individual patient as not all regimens
require addition of RBV for optimal virological efficacy. However, more data is needed in
order to conclude on the clinical utility of these SNPs.
A limitation of this study is that RBV concentrations were not available. A previous study
showed higher RBV concentrations at week 4 among patients with normal ITPase activity
compared to patients with ITPase deficiency [9]. This could be explained by the reduced hemo-
lytic anemia that was present in the patients with ITPase deficiency, generating a larger distri-
bution volume for the intracellular forms of RBV, leading to lower extracellular concentrations
of RBV. On the other hand, lower plasma concentrations of RBV could have led to the protec-
tion against anemia. In contrast, another study among 546 patients showed no association
between ITPase deficiency and RBV levels (p = 0.11) [13]. Finally, due to the retrospective
character of the study, we were not able to measure ITPase activity directly, as this requires
freshly acquired erythrocytes. Nevertheless, classification of the predicted ITPase activity by
combining the two genotypes has been suggested to be reliable [23, 24].
In conclusion, this real-world study showed that ITPase deficiency is associated with the
protection against hemolytic anemia among Caucasian patients with chronic HCV infection
who are treated with PegIFN and RBV. This led to less dose reductions of RBV and PegIFN as
well as less administration of blood transfusions and EPO. Since treatment efficacy is hampered
by dose reductions, patients with normal ITPase activity may benefit from early strategies in
order to improve treatment adherence.
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